版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、CRO 領(lǐng)域臨床試驗(yàn)醫(yī)學(xué)撰寫 領(lǐng)域臨床試驗(yàn)醫(yī)學(xué)撰寫 SOP(中英文對(duì)照 中英文對(duì)照)All sponsor/CRO personnel will be issued with copies of the most current SOPs and will be required to undertake clinical studies in accordance with those SOPs. They will be requi
2、red to sign a SOP compliance statement stating that they will conform with the requirements of the SOP and specifying the SOPs under consideration. 所有的申辦者/CRO 工作人員應(yīng)該發(fā)布最新版 SOP 文件,并且按照這些 SOP 進(jìn)行臨床研究。他們應(yīng)該簽署一個(gè) SOP 依從的聲明,表明他們將
3、遵從 SOP 要求,并詳細(xì)說明該 SOP 文件。SOPs will be reviewed at least annually (or more frequently, if necessary, because of urgently needed changes) to determine whether new SOPs or revisions to existing SOPs are needed. All supersede
4、d versions of SOPs must be available for audit and inspection. Thus, all master copies of superseded SOPs must be retained in the clinical study files. Reference copies of SOPs may be distributed to individuals in other
5、departments within the company, if required for the task being undertaken, and may be distributed to other external individuals (e.g. a CRO, if required for the task being undertaken). Documented permission to distribute
6、 SOPs externally must be obtained to protect confidentiality. Individual recipients of SOPs should not photo- copy the SOPs or distribute them to other personnel and personnel leaving the employ of the sponsor/CRO should
7、 immediately return SOPs.SOP 至少每年應(yīng)審查一次,以確定是否需要新的 SOP 或修訂現(xiàn)行的 SOP(如果需要,或者因?yàn)榫o急情況需要修改,則需要更頻繁修訂)。所有過時(shí)的 SOP 文件應(yīng)該妥善保存,以備稽查和視察。所有的過時(shí)的 SOP 的主文件必須保存在臨床研究文件中,分發(fā)給公司其他部門個(gè)人的 SOP 參考文件可以保存在公司。如果需要外部機(jī)構(gòu)承擔(dān)該任務(wù),或分發(fā)給其他外部個(gè)體(如 CRO 公司),就必須獲得 SO
8、P 外部分發(fā)許可文件,以保護(hù)該文件的機(jī)密性。SOP 的接收者不可以影印該 SOP,或分發(fā)給其它的人,離開申辦者/CRO 公司的雇員必須立刻歸還 SOP 文件。Under exceptional circumstances, waivers from the SOPs may be allowed, when it is known in advance that it will not be possible to comply wit
9、h the SOP. Waivers from SOPs must be requested in writing, with an explanation, and require written approval. Violation of SOPs (deliberately or through negligence) must be documented, with an explanation, and reported i
10、mmediately to a designated person. Consistent and deliberate non-compliance with the SOPs without written authorization will lead to disciplinary action.在特殊情況下,發(fā)起遵守 SOP 是允許的,當(dāng)事先知道不可能按照 SOP 完成時(shí),但必須做出書面解釋并經(jīng)過書面批準(zhǔn)。故意或由于疏忽而違反
11、 SOP,必須被記錄,并做出解釋,立即報(bào)告給相關(guān)負(fù)責(zé)人。沒有書面授權(quán)的連續(xù)故意的違反 SOP 應(yīng)該受到懲罰。l SOP number: each SOP will be numbered sequentially using five digits. The first set of three digits identifies a SOP and the second set of two digits indicat
12、es the revision number.SOP 的編號(hào):每個(gè) SOP 用 5 個(gè)數(shù)字序列編號(hào),前三個(gè)數(shù)字用來標(biāo)識(shí)該 SOP,后兩個(gè)數(shù)字表示版本號(hào)。l Issue date: this will be the date on which the SOP will take effect. It will be on or after the date of approval.頒布日期:是指該 SOP 生效日期,此日
13、期應(yīng)該是在批準(zhǔn)日期當(dāng)天或之后。l Supersedes: the number and date of the SOP which preceded the current SOP will be indicated;更新:應(yīng)該指出新版 SOP 之前的 SOP 的編號(hào)和頒布日期。l Last and next review dates: the last review date will be the dat
14、e on which the SOP was last reviewed. If the SOP remains unchanged after the review, the details for 'supersedes' will not change. The next review date will be the next scheduled date on which the SOP is planne
15、d to be reviewed.上次審核日期和下次審核日期:上次審評(píng)日期是指該 SOP 上次被審核的日期,如果該 SOP 經(jīng)審評(píng)后沒有變更,則“更新”項(xiàng)目的信息不變,下次審核日期是指計(jì)劃下次審評(píng)該 SOP 日期。l Approved by: the SOPs will be approved, with the dated signatures of at least one senior manager and sen
16、ior individual in the department to whom the SOP applies. The approvals confirm that the SOPs adequately describe the procedures developed and used by the sponsor/CRO.批準(zhǔn):SOP 的批準(zhǔn)最少要該部門一個(gè)高級(jí)經(jīng)理和一個(gè)高級(jí)個(gè)體簽字和日期。批準(zhǔn)是為了確認(rèn)該 SOP 充分描述了
17、申請(qǐng)人或 CRO 用到的程序。Each SOP will include the following sections in the text:每個(gè) SOP 的正文內(nèi)容應(yīng)該包括下面內(nèi)容:l Table of contents: the table of contents will include a list of items included in the SOP, with page numbers;目錄:包括 S
18、OP 所含項(xiàng)目及其頁碼列表。l Introduction: the introduction should briefly describe the rationale and scope of the SOP;簡介:應(yīng)當(dāng)簡要描述依據(jù)和適用范圍。l Contents: the contents of the SOP will follow the order noted in the table of
19、 contents and, in general, will follow the order in which procedures occur;內(nèi)容:SOP 的內(nèi)容與目錄中的順序一致,一般情況下,內(nèi)容應(yīng)該按照操作發(fā)生的順序編寫。 l Appendices to the SOP will be numbered and listed in the order in which they are addressed
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 眾賞文庫僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 臨床試驗(yàn)sop
- 藥物臨床試驗(yàn)制定sop的sop
- 開展藥物臨床試驗(yàn)sop
- 臨床試驗(yàn)藥物管理sop
- 臨床試驗(yàn)合同簽訂的sop
- 骨腫瘤專業(yè)臨床試驗(yàn)sop
- 臨床試驗(yàn)sop(包括病例要求計(jì)算)
- 藥物臨床試驗(yàn)質(zhì)量控制sop
- 藥物臨床試驗(yàn)sop的制定與實(shí)施
- 藥物臨床試驗(yàn)方案設(shè)計(jì)sop
- 藥物臨床試驗(yàn)方案設(shè)計(jì)sop
- 臨床試驗(yàn)設(shè)計(jì)與方案撰寫教育
- 臨床試驗(yàn)項(xiàng)目標(biāo)準(zhǔn)操作規(guī)程(sop)
- 制定藥物臨床試驗(yàn)sop的標(biāo)準(zhǔn)操作規(guī)程
- 瑞金醫(yī)院藥物臨床試驗(yàn)醫(yī)學(xué)檢查
- 藥物臨床試驗(yàn)制定sop的sop-廣州醫(yī)科大學(xué)附屬第三醫(yī)院
- 臨床試驗(yàn)手冊(cè)(1)——什么是新藥臨床試驗(yàn)
- 醫(yī)學(xué)科研,臨床試驗(yàn),知情同意如何開展
- 期臨床試驗(yàn)
- 國際臨床試驗(yàn)
評(píng)論
0/150
提交評(píng)論